These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 8851595

  • 1. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.
    James JK, Palmer SM, Levine DP, Rybak MJ.
    Antimicrob Agents Chemother; 1996 Mar; 40(3):696-700. PubMed ID: 8851595
    [Abstract] [Full Text] [Related]

  • 2. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.
    Benko AS, Cappelletty DM, Kruse JA, Rybak MJ.
    Antimicrob Agents Chemother; 1996 Mar; 40(3):691-5. PubMed ID: 8851594
    [Abstract] [Full Text] [Related]

  • 3. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis.
    Klepser ME, Patel KB, Nicolau DP, Quintiliani R, Nightingale CH.
    Pharmacotherapy; 1998 Mar; 18(5):1069-74. PubMed ID: 9758317
    [Abstract] [Full Text] [Related]

  • 4. Comparison of vancomycin pharmacodynamics (1 g every 12 or 24 h) against methicillin-resistant staphylococci.
    Lacy MK, Tessier PR, Nicolau DP, Nightingale CH, Quintiliani R.
    Int J Antimicrob Agents; 2000 Jun; 15(1):25-30. PubMed ID: 10856673
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
    Waineo MF, Kuhn TC, Brown DL.
    J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
    [Abstract] [Full Text] [Related]

  • 7. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG, Voth D, Nichol K, Karlowsky JA, Noreddin AM, Hoban DJ.
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Continuous vs. intermittent vancomycin therapy for Gram-positive infections not caused by methicillin-resistant Staphylococcus aureus.
    Duszynska W, Taccone FS, Hurkacz M, Wiela-Hojenska A, Kübler A.
    Minerva Anestesiol; 2016 Mar; 82(3):284-93. PubMed ID: 26184702
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
    Adane ED, Herald M, Koura F.
    Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
    [Abstract] [Full Text] [Related]

  • 11. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S, Tsuji Y, Mizoguchi A, Kasai H, Ishibashi T, Iwamura N, To H.
    J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
    [Abstract] [Full Text] [Related]

  • 12. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis.
    Fernández de Gatta Mdel M, Santos Buelga D, Sánchez Navarro A, Dominguez-Gil A, García MJ.
    Clin Pharmacokinet; 2009 Aug; 48(4):273-80. PubMed ID: 19492872
    [Abstract] [Full Text] [Related]

  • 13. In vitro and in vivo pharmacokinetics-pharmacodynamics of GV143253A, a novel trinem.
    Ferrari L, Iavarone L, Braggio S, Di Modugno E.
    Antimicrob Agents Chemother; 2003 Feb; 47(2):770-6. PubMed ID: 12543690
    [Abstract] [Full Text] [Related]

  • 14. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
    Abdel Hadi O, Al Omar S, Nazer LH, Mubarak S, Le J.
    J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
    [Abstract] [Full Text] [Related]

  • 15. Comparison of continuous infusion versus intermittent infusion of vancomycin in patients with methicillin-resistant Staphylococcus aureus.
    Jaruratanasirikul S, Julamanee J, Sudsai T, Saengsuwan P, Jullangkoon M, Ingviya N, Jarumanokul R.
    J Med Assoc Thai; 2010 Feb; 93(2):172-6. PubMed ID: 20301996
    [Abstract] [Full Text] [Related]

  • 16. In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure.
    Hamada Y, Kuti JL, Nicolau DP.
    Antimicrob Agents Chemother; 2016 Feb; 60(2):955-61. PubMed ID: 26621619
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model.
    Nicasio AM, Bulitta JB, Lodise TP, D'Hondt RE, Kulawy R, Louie A, Drusano GL.
    Antimicrob Agents Chemother; 2012 Feb; 56(2):682-6. PubMed ID: 22083484
    [Abstract] [Full Text] [Related]

  • 18. Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects.
    Ampe E, Delaere B, Hecq JD, Tulkens PM, Glupczynski Y.
    Int J Antimicrob Agents; 2013 May; 41(5):439-46. PubMed ID: 23523733
    [Abstract] [Full Text] [Related]

  • 19. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.
    Kitzis MD, Goldstein FW.
    Clin Microbiol Infect; 2006 Jan; 12(1):92-5. PubMed ID: 16460555
    [Abstract] [Full Text] [Related]

  • 20. Modified vancomycin dosing protocol for treatment of diabetic foot infections.
    Niu SC, Deng ST, Lee MH, Ho C, Chang HY, Liu FH.
    Am J Health Syst Pharm; 2008 Sep 15; 65(18):1740-3. PubMed ID: 18769001
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.